IL6 and acute respiratory distress syndrome: Advances in immune therapies have paved the way for the use of immunomodulators and anti-cytokine agents such as CD20-depleting agents and inhibitors of Janus kinase (JAK-i), tumor necrosis factor (TNF-i), and interleukin-6 inhibitors (IL6-i) to treat ARDs.